Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566964 · ClinicalTrials.gov registry record
Descriptive Analysis of Real-world Data Collected with ME&MGopen
A clinical trial, sponsored by Ad scientiam.
- Completed
- Registry status
- 236
- Enrollment target
NCT05566964: Completed study, sponsored by Ad scientiam.
NCT05566964 is a clinical trial that has completed, run by Ad scientiam. The registered enrollment target is 236 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05566964 has completed, sponsored by Ad scientiam.
- COMPLETED
- Registry status
- 236 participants
- Enrollment target
Study Summary
The ME\&MGopen smartphone application is an investigational software for research purposes only, developed by Ad Scientiam. It features digital tests to assess the respiratory capacity ("My Breathing" Test), dysarthria ("My Voice" Test), ptosis ("My eyelids" test), as well as upper and lower limb muscle function ("My arms" Test and "My legs" Test). The mobile app also includes e-questionnaires related to activities of daily living, pain, insomnia, quality of life and depression. The objectives of the study are to collect data on patients' symptoms with the application in a real life setting, to assess adherence to the use of the tool, user experience and satisfaction with the application, and safety of use.
Primary Outcome
Time in seconds measured with the ME\&MGopen smartphone application (holding the phone in one arm for as long as possible)
Interventions
- DEVICE ME&MGopen smartphone application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2025-01-10 |
What the finished NCT05566964 record still lists
NCT05566964 is an observational study that tracks outcomes without assigning an intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ME&MGopen smartphone application is the first listed.
NCT05566964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05566964 about?
NCT05566964 is a clinical study titled "Descriptive Analysis of Real-world Data Collected with ME&MGopen". The ME\&MGopen smartphone application is an investigational software for research purposes only, developed by Ad Scientiam. It features digital tests to assess the respiratory capacity ("My Breathing" Test), dysarthria ("My Voice" Test), ptosis ("My eyelids" test), as well as upper and lower limb mu...
What is the current status of trial NCT05566964?
This trial is currently completed. The enrollment target is 236 participants. The study started on 2023-02-27. Estimated completion is 2025-01-10.
What interventions are being tested in trial NCT05566964?
The interventions under investigation include: ME&MGopen smartphone application (DEVICE).
Who is sponsoring clinical trial NCT05566964?
This trial is sponsored by Ad scientiam, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI